Expanded access to pritelivir for resistant herpes in immunocompromised people
Part of Infections clinical trials.
This trial offers a new antiviral medicine called pritelivir to people with weakened immune systems who have herpes sores that do not get better with standard treatments. Taking pritelivir may help clear these resistant sores when other options have failed.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be 16 or older and have a weakened immune system (for example, due to HIV, organ or stem cell transplant, or medicines that suppress the immune system).
- Your herpes sores must be resistant to standard antivirals like acyclovir or valacyclovir, or you must have had to stop foscarnet due to side effects or it didn't help after at least 7 days.
- You must have a visible herpes sore or lesion at the start of treatment (it can be seen by a doctor, including by a scope).
- A swab test to confirm the sore is caused by herpes is needed before starting, but treatment can start before results come back.
- You must be willing to use reliable birth control (or abstain from sex) if you are of childbearing age, and have negative pregnancy tests if female.
- You must not be on dialysis or have very severe kidney disease, and your liver and blood counts must be within safe limits (checked by a doctor).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests whether acyclovir, an antiviral drug, can help patients with pneumonia who are on breathing support and have herpes simplex virus in their lung fluid. The goal is to see if it improves recovery.
This trial tests a new drug, VG2025, given through a vein for people with advanced solid tumors that have stopped responding to standard treatments. It aims to see if the drug is safe and if it can help shrink or control the tumors.
This study tests an investigational medication called UB-621, given as repeated doses, to see if it is safe and effective in reducing recurrent genital herpes outbreaks in adults. If you have frequent outbreaks (6 to 12 per year), this trial might help you find a new treatment option.
This trial tests whether giving the antiviral drug acyclovir early can help people on ventilators who show signs of herpes virus in the throat. The goal is to reduce complications and improve recovery.
This Phase 1 trial tests the safety and early effects of VG2025 in people with advanced solid cancers that have stopped responding to standard treatments. It’s mainly looking for side effects and how the body processes the drug, and it may offer a new option when other treatments haven’t worked.
This trial tests whether a medicine called acyclovir can prevent herpes simplex outbreaks in people who also have an autoimmune rheumatic disease. It may help reduce the number of painful cold sores or genital herpes episodes you experience.
Hear when a new HSV trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.